HomeCompareAPETF vs PFE

APETF vs PFE: Dividend Comparison 2026

APETF yields 718.80% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APETF wins by $1131771.97M in total portfolio value
10 years
APETF
APETF
● Live price
718.80%
Share price
$0.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1131772.02M
Annual income
$888,591,182,399.60
Full APETF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — APETF vs PFE

📍 APETF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPETFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APETF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APETF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APETF
Annual income on $10K today (after 15% tax)
$61,098.33/yr
After 10yr DRIP, annual income (after tax)
$755,302,505,039.66/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, APETF beats the other by $755,302,482,719.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APETF + PFE for your $10,000?

APETF: 50%PFE: 50%
100% PFE50/50100% APETF
Portfolio after 10yr
$565886.03M
Annual income
$444,295,604,329.16/yr
Blended yield
78.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

APETF
No analyst data
Altman Z
-51.3
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APETF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPETFPFE
Forward yield718.80%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1131772.02M$49.6K
Annual income after 10y$888,591,182,399.60$26,258.71
Total dividends collected$1112177.82M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: APETF vs PFE ($10,000, DRIP)

YearAPETF PortfolioAPETF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$82,580$71,880.39$9,153$693.39+$73.4KAPETF
2$643,119$554,758.02$8,593$849.25+$634.5KAPETF
3$4,725,839$4,037,701.80$8,336$1,066.78+$4.72MAPETF
4$32,785,892$27,729,244.37$8,437$1,384.80+$32.78MAPETF
5$214,869,578$179,788,673.38$9,013$1,875.40+$214.86MAPETF
6$1,331,111,136$1,101,200,687.10$10,306$2,680.72+$1331.10MAPETF
7$7,799,903,883$6,375,614,967.64$12,820$4,101.38+$7799.89MAPETF
8$43,260,992,969$34,915,095,814.80$17,673$6,826.70+$43260.98MAPETF
9$227,271,808,342$180,982,545,864.91$27,543$12,591.86+$227271.78MAPETF
10$1,131,772,017,326$888,591,182,399.60$49,560$26,258.71+$1131771.97MAPETF

APETF vs PFE: Complete Analysis 2026

APETFStock

AlphaGen Intelligence Corp. operates as a game and software development company in North America and internationally. It holds a portfolio of assets in gaming, generative AI, technology, and content production services. The company owns and operates Shape, a metaverse studio, which builds the future of web3 gaming experiences and supporting companies as their metaverse partner to design and build leading brand and virtual retail experiences; MANA, a white-label SaaS solution that allows brands and other organizations to launch their own gaming platforms without having to fund technological or backend systems; and GamerzArena, a gaming platform that provides an esports ecosystem for all gamers that provides video game contests where gamers can compete for cash and prizes in leadership and bracket formats. AlphaGen Intelligence Corp. has a strategic partnership with XCAVE Studios Inc. to develop next-generation branded experiences in Fortnite. The company was formerly known as Alpha Metaverse Technologies Inc. and changed its name to AlphaGen Intelligence Corp. in June 2023. The company was incorporated in 2019 and is based in Vancouver, Canada.

Full APETF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this APETF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APETF vs SCHDAPETF vs JEPIAPETF vs OAPETF vs KOAPETF vs MAINAPETF vs JNJAPETF vs MRKAPETF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.